Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

Recruiting now · Phase 1

Conditions studied: Multiple Myeloma

In brief

This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.

Key facts

Study ID

NCT07333261

Run by

Susan Bal

People needed

25

Starts

2026-02-09

Expected to finish

2041-12-01

Last updated by the study team

2026-02-13

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18 years with no upper age limit
• NDMM with indication for initiation of therapy diagnosed within last 12 months. Pretreatment parameters necessary for disease characterization and response assessment must be available.
• Not eligible for ASCT by institutional criteria or deferring ASCT due to personal preference.
• ECOG performance status 0-1
• Adequate organ function

You may not qualify if…

• Known active or history of central nervous system (CNS) involvement of MM.
• Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS or clinically significant amiloidosis.
• Prior history of other malignancies
• Uncontrolled infection
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.